WHAT THIS PAPER ADDS Most contemporary research focuses on the outcome of invasive procedures for critical limb ischaemia (CLI), but little is known about the outcome of patients managed conservatively. The aim of this study was to investigate amputation free survival and overall survival in patients with CLI who did or did not undergo revascularisation, and to explore clinical characteristics associated with clinical outcomes in these patients. Conservative management for some of the CLI patients appears warranted. Hence, surgeons and interventional radiologists should reconsider their current practice. Better patient selection would save unnecessary revascularisation and preoperative diagnostic procedures.
INTRODUCTION
Chronic critical limb ischaemia (CLI) is associated with a high risk of lower limb amputation, diminished quality of life, and substantial mortality. 1, 2 The Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) guidelines 3 recommend diagnostic staging and revascularisation for all patients with CLI. The main goals of endovascular and open revascularisation are pain relief and the prevention of lower limb amputation.
Revascularisation is not always possible because patients with CLI often have severe comorbidities or because it is not technically feasible. In this case patients are treated conservatively with analgesics and optimal wound care or with primary amputation. Two systematic reviews reported 1 year AFS rates of 55% and 57 in patients with CLI without options for revascularisation. 4, 5 Although patients with CLI have a poor prognosis in terms of amputation free survival (AFS), there is evidence to suggest that some patients who are not suitable candidates for revascularisation carry on well. 6e9 Despite optimal diagnostics and technical success, not all revascularisation procedures are successful and additional interventions may be necessary to maintain patency or achieve wound healing. Furthermore, complications such as graft occlusion and wound infection are relatively common after bypass surgery. 10, 11 Even if technically successful, revascularisation procedures do not always outperform non-interventional treatment. In some patients amputation is necessary despite adequate revascularisation, 12 and in other patients wounds heal despite a failed, or even without, revascularisation. 9 Most contemporary research focuses on outcomes of invasive procedures for CLI, but few data are available on the outcome of patients managed conservatively. The aim of this study was to investigate AFS and overall survival (OS) in patients with CLI who did or did not receive revascularisation, and to explore clinical characteristics associated with clinical outcome in these patients. By gaining insight into the outcome after conservative management, improved patient selection for costly revascularisation procedures may follow.
METHODS
This study was conducted and reported in accordance with the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) statement. 13 Ethical approval of the local Institutional Review Board was waived since this was a retrospective observational study.
Patient selection
All consecutive patients with chronic CLI presenting between January 2010 and January 2014 were selected for this retrospective study by evaluating vascular laboratory data and medical charts. Only patients with clinical symptoms of ischaemic rest pain or tissue loss and a systolic ankle pressure below 50 mmHg or a systolic toe pressure below 30 mmHg were eligible. If only one of these two parameters was present (e.g., low ankle pressure but no rest pain or tissue loss) the patient was not included. Other exclusion criteria were acute limb ischaemia, Buerger's disease, or vasculitis. Patients who were treated elsewhere and visited the hospital for a second opinion were also excluded. When CLI was demonstrated during an earlier examination (i.e., before January 2010) and the pressure measurement (showing CLI) was for follow-up purposes, the date of diagnosis was set at the date of the first clinical manifestation of CLI.
Data collection and outcome measures
Patient characteristics including age, gender, smoking habits, body mass index (BMI), comorbidities diabetes mellitus, cerebrovascular disease, end stage renal disease (ESRD), chronic obstructive pulmonary disease (COPD), heart disease, hypertension, presence of ischaemic rest pain (Fontaine stage III) or presence of ulceration or gangrene (Fontaine Stage IV) and prior revascularisation procedures were obtained from clinical charts and operation records. "Cerebrovascular disease" was defined as a previous transient ischaemic attack (TIA) or stroke, and "heart disease" as a previous myocardial infarction, angina pectoris, congestive heart failure, or prior coronary intervention. "ESRD" was defined as current haemodialysis, peritoneal dialysis, or previous kidney transplantation. Follow-up data included information about the revascularisation procedures performed, limb salvage and survival.
Patients were divided into one of the following three groups: "invasive" if the revascularisation took place within 6 weeks of presentation, "deferred invasive" if the revascularisation was conducted after more than 6 weeks of conservative management, and "permanently conservative" when no revascularisation was done between diagnosis and death or the last follow-up. The 6 week period was chosen as it was assumed that primary invasive treatment would have been completed within that period. Patients who immediately underwent a primary major amputation were excluded from the analysis.
Data of the included patients were collected until the patient's last follow-up visit or date of death. When there were no follow-up data available in the clinical charts, the patient's family physician was contacted to obtain additional information about any revascularisation procedures performed elsewhere, limb salvage, and survival.
The primary outcome of this study was AFS, defined as the time the patient remained alive without major amputation (i.e., proximal to the ankle joint) of the affected limb after they were diagnosed with CLI. Furthermore, OS was assessed.
Statistical analyses
Statistical analysis was performed using Statistical Package for the Social Sciences version 21 (SPSS Inc., Armonk, NY, USA). Descriptive statistics were expressed as means and standard deviations, or medians and interquartile ranges (IQR), whenever appropriate. One-way analysis of variance (ANOVA) was used to analyse differences between the three groups with normally distributed continuous variables and KruskaleWallis was used for non-normally distributed continuous variables. The chi-square and Fisher exact tests were used to compare categorical variables where appropriate. A p value < .05 was taken to be significant. AFS and OS were estimated using KaplaneMeier survival curves, and differences between groups were analysed using the Bre-sloweWilcoxon method. A Cox proportional hazards regression analysis was performed to detect factors that were independently associated with AFS and OS. In addition to type of treatment, variables were entered in the multivariable model when showing a (nearly) significant (i.e. p < .10) association in the univariable analysis.
RESULTS
A total of 153 patients with an ankle pressure below 50 mmHg or a systolic toe pressure below 30 mmHg in combination with documented chronic ischaemic rest pain or tissue loss were identified. Nine (5.9%) of these patients were immediately planned for primary amputation and were excluded from further analysis.
The mean age of the remaining 144 patients with chronic CLI was 71.2 years (SD 13.4) and 50.7% of the patients were female (N ¼ 73). As shown in Table 1 (clinical characteristics), the majority of patients suffered from ischaemic tissue loss (Fontaine Stage IV). There were no significant differences at baseline between the three groups. Median follow-up was 99 weeks (IQR 34e195 weeks). The treatment flow chart is shown in Fig. 1 . Within 6 weeks of diagnosis, 96 patients (66.7%) underwent a revascularisation, the majority (70.8%; N ¼ 68) an endovascular procedure. Deferred invasive treatment was provided in 18.1% (N ¼ 26) patients. Of these, 69.2% (N ¼ 18) underwent an endovascular revascularisation, 26.9% (N ¼ 8) underwent bypass surgery and one patient had a hybrid procedure. In the deferred invasive group, the median time between diagnosis and revascularisation was 17 weeks (IQR 9e45 weeks). In the deferred group, revascularisation was not performed within 6 weeks of initial presentation because logistics were not in place (bed, ITU, theatre, personal preferences of the patient) or because direct revascularisation was deemed not necessary based on the initial presentation of symptoms (e.g., a good healing tendency or limited tissue loss). Another 22 patients (15.3%) were treated permanently conservatively. Various reasons determined the decision not to perform revascularisation in these patients. In nine patients it was omitted due to comorbidities, in seven patients due to a good healing tendency or declining symptoms, and in three patients there were no options for revascularisation. In the remaining three patients the reason not to revascularise was unknown.
Re-interventions in the ipsilateral limb
Many patients needed additional interventions in the initially treated limb. In the invasive group, 45 patients (46.9%) underwent additional revascularisation procedures. Endovascular revascularisation was performed in 32 patients (in total 42 procedures, 1e3 procedures per patient) and 28 patients underwent surgical revascularisation (in total 33 procedures, 1e2 procedures per patient). In the deferred invasive group, 14 patients (53.8%) underwent additional revascularisation procedures in the initially revascularised limb. Endovascular revascularisation was performed in 12 patients (in total 18 procedures, 1e3 procedures per patient) and six patients underwent a surgical revascularisation (in total 9 procedures, 1e3 procedures per patient).
Amputation free and overall survival
As shown in Fig. 2 , the 1 year estimated AFS was 67.3% in the invasive group, 83.6% in the deferred invasive group, and 72.7% in the permanently conservative group, and after 2 years AFS was 56.0%, 74.8%, and 54.2%, respectively. AFS was not statistically different between the three groups (BresloweWilcoxon p ¼ .16). Also, when comparing AFS between conservatively treated patients and invasively treated patients (directly invasive and deferred invasive combined) no statistical difference was found (Breslowe Wilcoxon p ¼ 0.71). It is worth noting that AFS was completely driven by mortality among conservatively treated patients, and mortality was the largest driver of AFS among invasively treated patents. Major amputation was present in invasively treated patients only (18 of the 49 events after four years). Fig. 3 shows the KaplaneMeier curves of OS. After 1 year, the estimated OS was 77.3% in the invasive group, 87.8% in the deferred invasive group, and 72.7% in the permanently conservative group, and after 2 years the OS was 64.6%, 83.4% and 54.2%, respectively. As was the case for AFS, there was no statistically significant difference between the three curves for OS (BresloweWilcoxon p ¼ .09). In addition, there was also no statistically significant difference in OS between conservatively treated patients and those treated invasively (BresloweWilcoxon p ¼ .13). Table 2 presents the Cox proportional hazards model of risk factors predictive of the time to either major amputation or death. The type of treatment was not a significant predictor of AFS. Statistically significant predictors of a shorter AFS (HR >1.0) were higher age at diagnosis of CLI, COPD, and heart disease. The Cox proportional hazards model of risk factors predictive of the time to death (OS) is shown in Table 3 . Statistically significant predictors of shorter survival (HR >1.0) were higher age at diagnosis of CLI, hypertension, and COPD. Again, type of treatment was not a significant predictor of OS in either the univariable or multivariable models.
DISCUSSION
Most contemporary research focuses on outcome of invasive procedures for CLI, and does not report the outcome of conservative management for patients from the same centre in the same period. Yet, results of conservative treatment are helpful to put the assumed benefits of interventions into perspective, and to help physicians and patients guide clinical decision making. There is evidence to suggest that the prognosis of conservative treatment of CLI has improved over the years probably because of advances in medical treatment. 14 Yet, this latest systematic review reports a 1 year major amputation rate as high as 22% (95% CI, 2e42%) and a mortality rate of 22% (95% CI, 12e33%). 14 In the present study it was found that the AFS in patients with CLI was as expected, and that AFS was similar for all treatments given. It was also observed that most patients died before a major amputation was necessary. Despite the finding that mortality was the main driver of AFS, it is unlikely that all patients died of (septic) complications of CLI. The prognosis of patients with CLI is largely determined by their comorbidities. 15e18 In this cohort, advanced age, COPD, and heart disease were found to be independent predictors of poor AFS, whereas the stage of CLI was not associated with AFS.
Many patients required one or more additional interventions because of insufficient clinical improvement or complications of the initial revascularisation procedure. Hence, revascularisation does not seem to be a truism for all patients with CLI, which challenges the recommendations of the current international (TASC II) guidelines. 3 have an adverse effect on the patients' quality of life. 10, 11, 19 Therefore, vascular surgeons should redirect their focus towards fewer and less invasive treatment procedures and optimisation of the palliative care of fragile patients with a limited life expectancy. 20 In these situations, shared decision making may be the preferred approach when deciding whether or not to perform a revascularisation. 21, 22 In order to make a treatment decision that is consistent with the personal values of the patient, the surgeon should assess the patient's expectations and preferences.
The difficulty, however, lies in selecting the appropriate management for the right patient. Clinical judgement seemed to perform well for selecting patients for conservative treatment in this cohort, because none of these patients needed a major amputation before they died. Yet, identifying patients with a high likelihood of a poor outcome after revascularisation is probably more difficult, given the high amputation rate after revascularisation in the present study. Attempts might have been made to save the limb, even though it was very unlikely beforehand that the intervention would be successful. To generate more evidence about the outcomes after conservative therapy, it is suggested that prospective studies such as the BASIL-2 23 (vein bypass first versus endovascular therapy first) also report on the outcome of conservatively treated patients who were not suitable for trial participation. Promising tools for the prediction of outcome after revascularisation and the identification of patients who might not benefit from revascularisation are perfusion angiography 24 and the Wound, Ischaemia, and foot Infection (WIfI) classification system. 25 The WIfI stages were shown to correlate well with clinical outcomes such as major amputation and one year AFS. 25 
Study limitations
This study obviously suffers from selection bias as it is an observational study rather than a randomised controlled trial. However, the impact of this bias is unclear. One reason for the apparently non-superior outcome in patients with immediate revascularisation could be that these already had more advanced disease and had a worse overall clinical status, with a higher risk of amputation than patients who were managed conservatively or deferred invasively. So, it is conceivable that patients with large ulcers and gangrene would have undergone prompt revascularisation whereas those with smaller ulcers may have been treated conservatively, at least initially. On the other hand, patients who reached this advanced stage may have had unreconstructible arterial disease or refused further invasive treatment, leaving conservative or even palliative care as an option of last resort, with surprisingly good results. Second, the decision whether or not to perform open or endovascular revascularisation is usually determined by consensus in a multidisciplinary team meeting. 26 In the In the multivariable model, the level of significance was defined as a p-value less than .05. a Fontaine III, ischaemic rest pain without tissue loss; Fontaine IV, ischaemic ulceration or gangrene. Variables were entered in the multivariable model when showing a (nearly) significant (i.e. p <.10) association in the univariable analysis. In the multivariable model, the level of significance was defined as a p-value less than .05. a Fontaine III, ischaemic rest pain without tissue loss; Fontaine IV, ischaemic ulceration or gangrene. study hospital an "endovascular first" strategy was practised. The decision to perform a revascularisation is based on clinical symptoms such as progression of tissue loss, the intensity of pain, and comorbidity. The reason a patient underwent conservative treatment could only be determined by a retrospective review of clinical charts. Unfortunately, pain scores, walking distance, and wound characteristics could not be included in the analyses because they were not systematically recorded in the clinical charts and notes of surgical procedures. Furthermore, effect of conservative management on wound healing, pain relief and quality of life could not be assessed.
CONCLUSION
The present study provides evidence that not all CLI patients require revascularisation because AFS and OS were found not to differ between the three treatment strategies. AFS was more driven by mortality rather than by major amputation. Statistically significant predictors of poor AFS were higher age at diagnosis of CLI, COPD, and heart disease, whereas the treatment given was not.
Further prospective studies are required to assess relevant additional patient outcomes after conservative therapy. The challenge for future studies is to develop better ways to identify subgroups of CLI patients in whom revascularisation may be omitted without affecting their health outcome. This would help reduce overtreatment and costs and improve the patients' quality of life.
